Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced two regulatory milestones for the companys
investigational vaccine for Ebola Zaire, V920 (rVSVG-ZEBOV-GP, live
attenuated): the U.S. Food and Drug Administration (FDA) has granted the
vaccine candidate Breakthrough Therapy Designation, and the European
Medicines Agency (EMA) has granted PRIME (PRIority MEdicines)
status.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Skip Irvine, 215-652-6059orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more